drugset / Trial / NCT02201381

Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer

NCT02201381

Phase 3 Withdrawn Health Clinics Limited
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree of response and changes in biochemical markers (such as glucose and lipid levels).

Timeline

Start
2022-05-23
Primary completion
2027-05-23
Completion
2027-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg Oral
Subject Doxycycline Small molecule 100 mg Oral
Subject Mebendazole Small molecule 100 mg Oral
Subject Metformin Small molecule 1000 mg Oral

Indications